血浆蛋白C与血管性血友病因子在多发性骨髓瘤中的临床意义

doi:10.3969/j.issn.1673-8640.2021.11.004

检验医学 ›› 2021, Vol. 36 ›› Issue (11): 1110-1113.DOI: 10.3969/j.issn.1673-8640.2021.11.004

血浆蛋白C与血管性血友病因子在多发性骨髓瘤中的临床意义

陈霞¹, 陈熙²()

1.中国人民解放军陆军特色医学中心全科医学科,重庆 400042
2.重庆医科大学附属第一医院检验科,重庆 400016

收稿日期:2020-10-10 出版日期:2021-11-30 发布日期:2021-12-20
通讯作者: 陈熙
作者简介:陈熙, E-mail： 191132874@qq.com。
陈霞,男,1986年生,硕士,技师,主要从事血栓与止血研究。
基金资助:
国家自然科学基金青年项目(81803110)

Clinical significance of plasma protein C and von Willebrand factor in patients with multiple myeloma

CHEN Xia¹, CHEN Xi²()

1. Health Management Center,Army Medical Center of People's Liberation Army,Chongqing 400042,China
2. Department of Clinical Laboratory,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China

Received:2020-10-10 Online:2021-11-30 Published:2021-12-20
Contact: CHEN Xi

摘要/Abstract

摘要：

目的探讨血浆蛋白C（PC）活性和血管性血友病因子抗原（vWF：Ag）含量变化在多发性骨髓瘤（MM）治疗和预后评估中的临床意义。方法选取81例MM患者,根据国际分期系统（ISS）的分期标准分为Ⅰ期组、Ⅱ期组、Ⅲ期组。以14名体检健康者为对照组。比较MM各组与对照组血浆总vWF：Ag和PC的差异。结果 MM不同分期患者vWF：Ag含量均高于对照者（P<0.05）;男性MM患者vWF：Ag含量高于女性（P<0.05）;PC活性随疾病进展而逐渐降低,Ⅱ期与Ⅲ期MM患者的PC活性低于对照者（P<0.05）。PC活性随着患者年龄的增加而降低（P<0.05）;Ⅲ期MM患者PC活性与年龄呈负相关（r=-0.361,P<0.05）,PC与vWF：Ag呈正相关（r=0.363,P<0.05）。结论 vWF：Ag和PC在一定程度上可反映MM的疾病严重程度,且两者具有相关性,对MM的治疗和预后评估具有一定的意义。

关键词: 血管性血友病因子, 蛋白C, 多发性骨髓瘤

Abstract:

Objective To investigate the clinical significance of plasma protein C（PC） activity and von Willebrand factor antigen（vWF：Ag） level in the treatment and prognosis of multiple myeloma（MM）. Methods Totally,81 patients who were diagnosed with MM were enrolled and classified into 3 groups according to international staging system（ISS）staging criteria（stage Ⅰ,Ⅱ and Ⅲ groups）. A total of 14 healthy subjects were enrolled as control group. PC activity and vWF：Ag level were determined and compared between MM and control groups. Results The levels of vWF：Ag in MM groups were higher than that in control group（P<0.05）. The level of vWF：Ag in males was higher than that in females（P<0.05）. The activities of PC in stage Ⅱ and stage Ⅲ were lower than that in control group（P<0.05）,and PC activity had a decreasing trend with disease progress. PC activity was decreased with ages（P<0.05）. The activity of PC was negatively correlated with ages in stage Ⅲ group（r=-0.361,P<0.05）. There was a positive correlation between PC activity and vWF：Ag level in stage Ⅲ group（r=0.363,P<0.05）. Conclusions PC and vWF：Ag would reflect the disease severity in some degree and are correlated,which play roles in the treatment and prognosis of patients with MM.

Key words: Von Willebrand factor, Protein C, Multiple myeloma

中图分类号:

R446.1

陈霞, 陈熙. 血浆蛋白C与血管性血友病因子在多发性骨髓瘤中的临床意义[J]. 检验医学, 2021, 36(11): 1110-1113.

CHEN Xia, CHEN Xi. Clinical significance of plasma protein C and von Willebrand factor in patients with multiple myeloma[J]. Laboratory Medicine, 2021, 36(11): 1110-1113.

图/表 5

参考文献 16

[1]	邢健, 刘国强, 徐敏, 等. 多发性骨髓瘤的免疫表型特征及其意义[J]. 疑难病杂志, 2012, 11(2):115-117.
[2]	MAHINDRA A, LAUBACH J, RAJE N, et al. Latest advances and current challenges in the treatment of multiple myeloma[J]. Nat Rev Clin Oncol, 2012, 9(3):135-143.
[3]	DI PASQUALE I, BUDDE U, TONA F, et al. Link between von Willebrand factor multimers,relapses and coronary microcirculation in patients with thrombotic thrombocytopenic purpura in remission[J]. Thromb Res, 2018, 173:42-47. DOI URL
[4]	ZANGARI M, ELICE F, FINK L, et al. Hemostatic dysfunction in paraproteinemias and amyloidosis[J]. Semin Thromb Hemost, 2007, 33(4):339-349. DOI URL
[5]	张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2008.
[6]	GUO L, TONG D, YU M, et al. Phosphatidylserine-exposing cells contribute to the hypercoagulable state in patients with multiple myeloma[J]. Int J Oncol, 2018, 52(6):1981-1990.
[7]	KAWASHIMA I, TAKANO K, KUMAGAI T, et al. Combined coagulopathy can induce both hemorrhagic and thrombotic complications in multiple myeloma[J]. Intern Med, 2018, 57(22):3303-3306. DOI URL
[8]	华佳叶, 冯莹, 庞缨, 等. 血液肿瘤患者中血管性血友病因子、D二聚体、抗凝血酶检测的意义[J]. 血栓与止血学, 2006, 12(3):123-125.
[9]	LI F, XU Y, DENG P, et al. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma[J]. Oncotarget, 2015, 6(11):9434-9444. DOI URL
[10]	PATI M L, VITALE P, FERORELLI S, et al. Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability[J]. Eur J Med Chem, 2019, 164:59-76. DOI URL
[11]	BOLLEN L, PEETERMANS M, PEETERS M, et al. Active PAI-1 as marker for venous thromboembolism:case-control study using a comprehensive panel of PAI-1 and TAFI assays[J]. Thromb Res, 2014, 134(5):1097-1102. DOI URL
[12]	TSAI A W, CUSHMAN M, ROSAMOND W D, et al. Coagulation factors,inflammation markers,and venous thromboembolism:the longitudinal investigation of thromboembolism etiology(LITE)[J]. Am J Med, 2002, 113(8):636-642. DOI URL
[13]	AUWERDA J J, SONNEVELD P, DE MAAT M P, et al. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma[J]. Haematologica, 2007, 92(2):279-280. DOI URL
[14]	GIATROMANOLAKI A, BAI M, BOURANTAS K L, et al. Hypoxia and activated VEGF/receptor pathway in multiple myeloma[J]. Anticancer Res, 2010, 30(7):2831-2836.
[15]	DÜHRSEN U, PAAR D, BRITTINGER G. Lupus anticoagulant associated syndrome in benign and malignant systemic disease[J]. Klin Wochenschr, 1987, 65(17):818-822. DOI URL
[16]	KOUTSI A, PAPAPANAGIOTOU A, PAPAVASSILIOU A G. Thrombomodulin:from haemestasis to inflammation and tumourigenesis[J]. Int J Biochem Cell Biol, 2008, 40(9):1669-1673. DOI URL

组别	例数	PC/%	vWF：Ag/%
Ⅰ期组	7	94.96±31.36	284.14±93.15^**#
Ⅱ期组	13	95.57±24.58^*	152.15±64.17
Ⅲ期组	61	87.65±33.85^**	230.31±113.07^*#
对照组	14	116.77±19.52	150.36±78.48

组别	例数	PC/%	vWF：Ag/%
Ⅰ期组	7	94.96±31.36	284.14±93.15^**#
Ⅱ期组	13	95.57±24.58^*	152.15±64.17
Ⅲ期组	61	87.65±33.85^**	230.31±113.07^*#
对照组	14	116.77±19.52	150.36±78.48

年龄	例数	PC/%	vWF：Ag/%
<58岁	15	106.23±41.50	226.87±83.22
58~68岁	27	83.63±31.33^*	236.00±150.11
>68岁	19	78.71±25.82^*#	224.95±67.78
F值		1.340	3.989
P值		0.046	0.941

年龄	例数	PC/%	vWF：Ag/%
<58岁	15	106.23±41.50	226.87±83.22
58~68岁	27	83.63±31.33^*	236.00±150.11
>68岁	19	78.71±25.82^*#	224.95±67.78
F值		1.340	3.989
P值		0.046	0.941

性别	例数	PC/%	vWF：Ag/%
男性	35	98.88±38.89	239.35±66.24
女性	26	86.48±27.60	196.59±96.86
t值		0.747	0.480
P值		0.265	0.034

血浆蛋白C与血管性血友病因子在多发性骨髓瘤中的临床意义

Clinical significance of plasma protein C and von Willebrand factor in patients with multiple myeloma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 16

相关文章 15

编辑推荐

Metrics

[1]	钱蓓蓓, 陶佳莹, 毛佩敏, 刘晓艳. 不同孕期孕妇蛋白C、蛋白S、纤溶酶原变化及其临床意义[J]. 检验医学, 2022, 37(9): 847-849.
[2]	王斌. ADAMTS-13活性与高危非ST段抬高型急性心肌梗死的相关性分析[J]. 检验医学, 2022, 37(6): 529-534.
[3]	宋金萍, 马晶, 黄国虹. 血管性血友病因子检测在老年慢性心力衰竭患者并发下肢静脉血栓中的临床意义[J]. 检验医学, 2022, 37(5): 438-442.
[4]	王洪玲, 李莉, 张春玲, 蔺丽慧, 丁静, 李会丹, 魏道林, 白萍. 浆细胞胞浆含明显颗粒κ轻链型多发性骨髓瘤临床回顾分析[J]. 检验医学, 2021, 36(8): 818-822.
[5]	陈佳, 金炜, 姚震, 陆波, 金敏, 陈旭东, 胡晓波. 以腰痛为首发症状伴血清胶冻状多发性骨髓瘤1例[J]. 检验医学, 2020, 35(4): 393-394.
[6]	郭孟乔, 龚胜蓝, 张春玲, 张悦晟, 程辉, 杨建民, 唐古生. 多发性骨髓瘤继发急性B淋巴细胞白血病缓解后骨髓瘤复发1例报道[J]. 检验医学, 2020, 35(4): 395-397.
[7]	郑伟, 陆捷, 桂清荣, 王东云. 28例IgD型多发性骨髓瘤患者实验室检查特点和临床特征分析[J]. 检验医学, 2020, 35(3): 224-228.
[8]	徐凯红, 牧启田, 欧阳桂芳, 严笑. 153例多发性骨髓瘤的细胞遗传学分析[J]. 检验医学, 2020, 35(12): 1243-1247.
[9]	郑伟, 陆捷, 郝爱军, 张银辉. 5例双克隆型多发性骨髓瘤的实验室检测结果分析[J]. 检验医学, 2019, 34(8): 710-716.
[10]	张靖宇, 范洪, 路炳通, 胡海涛. 血清免疫球蛋白等因素对分离胶采血管血液分离效果的影响[J]. 检验医学, 2018, 33(4): 275-278.
[11]	丁慧, 盛慧明, 孙致信, 左雪梅, 黄忠华. 多发性骨髓瘤引起假性高胆红素血症1例报道[J]. 检验医学, 2018, 33(4): 376-378.
[12]	纪伟, 吴洪坤, 周琳. 多发性骨髓瘤非编码RNA的研究进展[J]. 检验医学, 2018, 33(3): 264-268.
[13]	李雯, 何爱丽, 张雯, 周挺. CS-5100全自动血凝仪检测抗凝血酶Ⅲ、蛋白C、蛋白S活性的性能验证[J]. 检验医学, 2018, 33(11): 1009-1012.
[14]	张靖宇, 陈立新, 王丽芳, 胡海涛, 王军, 范洪. 血清IgA水平对血清果糖胺水平的影响[J]. 检验医学, 2017, 32(3): 182-184.
[15]	钱定良, 闫绍荣, 刘凌云. 可溶性内皮细胞蛋白C受体和可溶性血栓调节蛋白在2 型糖尿病诊疗中的临床意义[J]. 检验医学, 2017, 32(3): 208-209.